NASDAQ$TNGX
Tango Therapeutics Inc · Q4 2025 earnings
Q4 2025 earnings · · Before market open · Investor relations
Briefing
TNGX reported Q4 2025 a net loss of $38.7M, diluted EPS of $-0.29.
For Q4 2025, TNGX reported net loss was $38.7M, diluted EPS was $-0.29. Management discusses segment performance, liquidity, and outlook in the earnings filing.
- Net loss $38.7M.
- Diluted EPS $-0.29.
- MD&A covers capital allocation, costs, and sector risks.
Headline financials
Revenue & EPS history
Tango Therapeutics · Revenue · Quarterly
$0
Forward guidance
The filing discusses operating priorities, liquidity, and sector risks; numeric multi-quarter bridges vary by issuer.
Tailwinds
- MD&A highlights strategic priorities and cash runway.
- Pipeline, product, or segment commentary supports the narrative.
Headwinds
- Ongoing losses or impairment charges for pre-profit names.
- Macro, rates, or input costs may pressure margins.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports · overlaid with Q4 2025
+0.6%
Avg return
Earnings day
+6.7%
Avg return
5 days after
+25.8%
Avg return
30 days after
58%
11 / 19 earnings
Positive
+36.4%
Q4 2025
Best reaction
-45.4%
Q3 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +8.6% | -12.1% | +31.7% | |
| Q4 2025 | +36.4% | +33.6% | +75.1% | |
| Q3 2025 | +0.2% | -1.7% | +23.6% | |
| Q1 2025 | +17.1% | +31.6% | +315.8% | |
| Q4 2024 | -6.5% | -21.0% | -36.9% | |
| Q3 2024 | -45.4% | -34.7% | -34.7% | |
| Q2 2024 | -1.8% | -5.7% | +20.9% | |
| Q1 2024 | -0.8% | -6.9% | -12.1% | |
| Q4 2023 | -9.7% | -14.4% | -17.4% | |
| Q3 2023 | +3.8% | -12.1% | +6.6% | |
| Q2 2023 | +1.2% | +120.9% | +113.5% | |
| Q1 2023 | +6.4% | +4.4% | -0.3% | |
| Q4 2022 | -9.4% | -5.3% | -21.6% | |
| Q3 2022 | -5.3% | +6.7% | -1.3% | |
| Q2 2022 | +22.4% | +32.8% | -8.1% | |
| Q1 2022 | -7.6% | +1.2% | -3.8% | |
| Q4 2021 | +0.3% | +6.8% | +1.3% | |
| Q3 2021 | +0.4% | +5.2% | -10.7% | |
| Q2 2021 | +1.1% | -2.2% | +49.4% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro